Prevention and Regression of Coronary Atherosclerosis

Kannel, 1976, Some lessons in cardiovascular epidemiology from Framingham, Am J Cardiol, 37, 269, 10.1016/0002-9149(76)90323-4 Keys, 1980, Seven countries: a multivariate analysis of health and coronary heart disease. Cambridge Stamler, 1986, for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screens of the multiple risk factor intervention trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022 The Multiple Risk Factor Intervention Trial Research Group, 1990, Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a prior hypothesis of the trial, JAMA, 263, 1795, 10.1001/jama.1990.03440130083030 Neaton, 1992, Multiple Risk Factor Intervention Trial Research Group: serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial, Arch Intern Med, 152, 1490, 10.1001/archinte.1992.00400190110021 Chen, 1991, Serum cholesterol and coronary heart disease in population with low cholesterol, BMJ, 303, 276, 10.1136/bmj.303.6797.276 Manolio, 1992, Cholesterol and heart disease in older persons and women: review of an NHLBI workshop, Ann Epidemiol, 2, 161, 10.1016/1047-2797(92)90051-Q Yusuf, 1988, Overview of results of randomized clinical trials in heart disease, II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA, 260, 2259 Lipid Research Clinics Program, 1984, The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering, JAMA, 251, 365, 10.1001/jama.1984.03340270043026 Davis, 1991, A single cholesterol measurement underestimates the risk of coronary heart disease, JAMA, 264, 3044, 10.1001/jama.1990.03450230080033 Consensus Development Conference, 1985, Lowering blood cholesterol to prevent heart disease, JAMA, 253, 2080, 10.1001/jama.1985.03350380096029 NCEP Expert Panel, 1988, Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults, Arch Intern Med, 148, 36, 10.1001/archinte.1988.00380010040006 Bradford, 1991, Expanded clinical evaluation of lovastatin (EXCEL) study results, Arch Intern Med, 151, 43, 10.1001/archinte.1991.00400010067008 Jacobs, 1992, McMillan G, et al, for Participants in the Conference on Low Cholesterol: Mortality Associations: report on the conference on low cholesterol: mortality associations, Circulation, 86, 1046, 10.1161/01.CIR.86.3.1046 Austin, 1989, Plasma triglycerides as a risk factor for coronary heart disease: the epidemiologic evidence and beyond, Am J Epidemiol, 129, 249, 10.1093/oxfordjournals.aje.a115130 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Dayton, 1969, A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis, Circulation, 39-40, 1 Hjermann, 1981, Effect of diet and smoking intervention on the incidence of coronary heart disease, Lancet, 248, 1465 Frick, 1987, Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes of risk factors and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Coronary Drug Project Research Group, 1975, Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021 Muldoon, 1990, Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials, BMJ, 301, 309, 10.1136/bmj.301.6747.309 Holme, 1990, An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence, Circulation, 82, 1916, 10.1161/01.CIR.82.6.1916 Smith, 1992, Should there be a moratorium on the use of cholesterol lowering drugs?, BMJ, 304, 431, 10.1136/bmj.304.6824.431 Keech, 1992, False negative total mortality results in cholesterol-lowering trials, Eur Heart J, 13, 162 Brensike, 1984, Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI type II coronary intervention study, Circulation, 69, 313, 10.1161/01.CIR.69.2.313 Arntzenius, 1985, Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden intervention trial, N Engl J Med, 312, 805, 10.1056/NEJM198503283121301 Blankenhom, 1987, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA, 257, 3233, 10.1001/jama.1987.03390230069027 Cashin-Hemphill, 1990, Beneficial effects of colestipolniacin on coronary atherosclerosis: a 4-year follow-up, JAMA, 264, 3013, 10.1001/jama.1990.03450230049028 Loaldi, 1989, Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris, Am J Cardiol, 64, 433, 10.1016/0002-9149(89)90417-7 Lichtlen, 1990, on behalf of the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine, Lancet, 335, 1109, 10.1016/0140-6736(90)91121-P Ornish, 1990, Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial, Lancet, 336, 129, 10.1016/0140-6736(90)91656-U Buchwald, 1990, Campbell GS, et al, and the POSCH Group. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on the surgical control of the hyperlipidemias (POSCH), N Engl J Med, 323, 946, 10.1056/NEJM199010043231404 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Kane, 1990, Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens, JAMA, 264, 3007, 10.1001/jama.1990.03450230043027 Waters, 1990, A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis, Circulation, 82, 1940, 10.1161/01.CIR.82.6.1940 Hahmann, 1991, Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy, Am J Cardiol, 67, 957, 10.1016/0002-9149(91)90167-J Watts, 1992, Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS), Lancet, 339, 563, 10.1016/0140-6736(92)90863-X Schuler, 1992, Regular physical exercise and low-fat diet effects on progression of coronary artery disease, Circulation, 86, 1, 10.1161/01.CIR.86.1.1 Rose, 1981, Strategy of prevention: lessons from cardiovascular disease, BMJ, 282, 1847, 10.1136/bmj.282.6279.1847 Komachi, 1971, Geographic and occupational comparisons of risk factors in cardiovascular diseases in Japan, Jpn Circ J, 35, 189, 10.1253/jcj.35.189 Hlatky, 1981, Plasma cholesterol: can it be too low?, Arch Intern Med, 141, 1132, 10.1001/archinte.1981.00340090028009 Oliver, 1988, Reducing cholesterol does not reduce mortality, J Am Coll Cardiol, 12, 814, 10.1016/0735-1097(88)90327-0 Frank, 1992, Will lowering population levels of serum cholesterol affect total mortality?, J Clin Epidemiol, 45, 333, 10.1016/0895-4356(92)90034-K Hulley, 1992, Health policy on blood cholesterol: time to change directions, Circulation, 86, 1026, 10.1161/01.CIR.86.3.1026 Ginsburg, 1991, Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels, Am J Cardiol, 68, 187, 10.1016/0002-9149(91)90742-4 Miller, 1992, Long-term predictors of subsequent cardiovascular events with coronary artery disease and “desirable” levels of plasma total cholesterol, Circulation, 86, 1165, 10.1161/01.CIR.86.4.1165 The SOLVD Investigators, 1991, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 The SOLVD Investigators, 1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003 Pfeffer, 1992, on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 Chobanian, 1990, Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit, Hypertension, 15, 327, 10.1161/01.HYP.15.3.327 Geisterfer, 1988, induces hypertrophy not hyperplasia of cultured rat aortic smooth muscle cells, Circ Res, 62, 749, 10.1161/01.RES.62.4.749 Campbell-Boswell, 1981, Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro, Exp Mol Pathol, 35, 854, 10.1016/0014-4800(81)90066-6 Naftilian, 1989, Induction of PDGF A chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells, J Clin Invest, 83, 1419, 10.1172/JCI114032 Powell, 1989, Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury, Science, 245, 186, 10.1126/science.2526370 Bell, 1990, Influence of the angiotensin system on endothelial and smooth muscle cell migration, Am J Pathol, 137, 7 Stampfer, 1993, The epidemiology of dietary antioxidants and risk of coronary heart disease, Can J Cardiol, 9, 99D